Vertex shuts down trial of liver drug, spurring a selloff
October 15, 2020 at 05:29 AM EDT
Shares of the Boston-based drugmaker fell after-hours on Wednesday, spurring a loss of around $7 billion in market cap, after discontinuing work on one of its next-generation drugs.
